Neuropathy Finally Gets Some Notice

Article

Studies look at women with peripheral neuropathy after treatment for early-stage breast cancer

I can’t believe it. I can’t believe it.

For years, I have watched new cancer studies, hoping to see one on peripheral neuropathy for women like me who were treated for early-stage breast cancer.

About six years after my treatment ended, my feet began to swell and were so painful that I was going down the list of painkillers trying to get relief. I finally gave up trying to figure it out and cure it, and have been on methadone since around 2000.

It is true that when your feet hurt, the world is just not the same.

I now wear orthotic shoes that help, and with the painkillers, I can get around as long as it does not include long walks or long days on my feet. My feet are double-wide and finding shoes has been a nightmare. I have tried electric shock, different kinds of drugs and every other conceivable cure to no avail. My feet hurt all the time and a few years after my feet began to hurt, I noticed I could not clap anymore.

I wrote a story on neuropathy for CURE a number of years ago, looking at which drugs cause neuropathy and all possible drugs and natural cures. Acupuncture does help with the pain, but has to be repeated frequently and at around $100 a pop, is just not sustainable.

I also now cannot clap because my hands hurt so much.

Part of my frustration has been the lack of information about the whys and hows from the cancer community. There has been a slow recognition that some specific new drugs cause neuropathy, but it seems like no research has looked at those of us treated many years ago who did not get those drugs.

Finally, not just one but two studies have shown up. They don’t say much except that we need to know more about neuropathy for women treated for early stage breast cancer. We don’t know much about it and there is no treatment, but they confirm I am not crazy. They confirm that other women treated for early stage breast cancer have neuropathy. And that it gets worse over time.

I know that some women have peripheral neuropathy as a late effect, or something that shows up after treatment ends. I have been willing to concede that I am an anomaly, and that my neuropathy is not normal if someone would tell me what to do about it.

I would love to be able to wear decent shoes and clap at the end of a performance. I’d appreciate anything that works just a little. In addition, it would be great if someone could tell me how to keep it from getting worse.

Related Videos
For patients with cancer, the ongoing chemotherapy shortage may cause some anxiety as they wonder how they will receive their drugs. However, measuring drugs “down to the minutiae of the milligrams” helped patients receive the drugs they needed, said Alison Tray. Tray is an advanced oncology certified nurse practitioner and current vice president of ambulatory operations at Rutgers Cancer Institute in New Jersey.  If patients are concerned about getting their cancer drugs, Tray noted that having “an open conversation” between patients and providers is key.  “As a provider and a nurse myself, having that conversation, that reassurance and sharing the information is a two-way conversation,” she said. “So just knowing that we're taking care of you, we're going to make sure that you receive the care that you need is the key takeaway.” In June 2023, many patients were unable to receive certain chemotherapy drugs, such as carboplatin and cisplatin because of an ongoing shortage. By October 2023, experts saw an improvement, although the “ongoing crisis” remained.  READ MORE: Patients With Lung Cancer Face Unmet Needs During Drug Shortages “We’re really proud of the work that we could do and achieve that through a critical drug shortage,” Tray said. “None of our patients missed a dose of chemotherapy and we were able to provide that for them.” Tray sat down with CURE® during the 49th Annual Oncology Nursing Society Annual Congress to discuss the ongoing chemo shortage and how patients and care teams approached these challenges. Transcript: Particularly at Hartford HealthCare, when we established this infrastructure, our goal was to make sure that every patient would get the treatment that they need and require, utilizing the data that we have from ASCO guidelines to ensure that we're getting the optimal high-quality standard of care in a timely fashion that we didn't have to delay therapies. So, we were able to do that by going down to the minutiae of the milligrams on hand, particularly when we had a lot of critical drug shortages. So it was really creating that process to really ensure that every patient would get the treatment that they needed. For more news on cancer updates, research and education, don’t forget to subscribe to CURE®’s newsletters here.
Yuliya P.L Linhares, MD, an expert on CLL
Yuliya P.L Linhares, MD, and Josie Montegaard, MSN, AGPCNP-BC, experts on CLL
Image of a man with a beard.
Image of a man with gray facial hair and a navy blue suit with a light orange tie.
Image of a woman with black hair.
Related Content